Ascend Acquires Beacon Gene Therapy Manufacturing Site

Ascend Advanced Therapies, a gene therapy development partner, has purchased Beacon Therapeutics’ contract, manufacturing, and controls team—along with the company's site, previously owned by UF Innovate | Accelerate graduate AGTC, located in Alachua, FL—a town considered to be a “biotech hub” in the state. The acquisition introduces a good manufacturing practice (GMP) plant into the fold, along with process and analytical development capabilities.

Celebrating a Mentor – College Honors Faculty Members With New Award Named for the Late Mavis Agbandje-McKenna, PhD

Mavis Agbandje-McKenna, PhD, a UF College of Medicine professor in the department of biochemistry and molecular biology and the director of the Center for Structural Biology, dedicated 32 years to advancing discoveries in adeno-associated viruses, or AAV, and other parvoviruses at UF before passing away in 2021. In addition to being a globally recognized parvovirus researcher, she demonstrated an unwavering commitment to training the next generation of scientists.

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases

UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.